JD Pharma
ActiveJD Pharma is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €515k and a net result of €49k. Equity is growing by ~35.4% per year across the filed fiscal years. Its solvency ranks better than 34% of 7954 sector peers (fiscal year 2025). The company has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals.
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · A punctual record breaks
This company filed 3 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
28 d late
2024
7 d early
2023
12 d early
2022
19 d early
2021
31 d late
2020
23 d early
2019
25 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
12-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€515k▲ 10.4%
2024 · €466k
2018: €62k
2019: €83k
2020: €113k
2021: €152k
2022: €185k
2023: €406k
2024: €466k
2018 → 2025
Net result
€49k▼ 18.8%
2024 · €60k
2018: €21k
2019: €24k
2020: €30k
2021: €38k
2022: €34k
2023: €221k
2024: €60k
2018 → 2025
Total assets
€1.65M▲ 18.9%
2024 · €1.39M
2018: €93k
2019: €222k
2020: €225k
2021: €261k
2022: €1.14M
2023: €1.41M
2024: €1.39M
2018 → 2025
Solvency
31.2%▼ 2.4pp
2024 · 33.6%
2018: 66.8%
2019: 37.4%
2020: 50.5%
2021: 58.1%
2022: 16.3%
2023: 28.9%
2024: 33.6%
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€152k-€185k▲ 22.1%€406k▲ 120%€466k▲ 14.7%€515k▲ 10.4%
Operating result€49k-€53k▲ 7.1%€305k▲ 475%€92k▼ 69.9%€75k▼ 17.7%
Net result€38k-€34k▼ 11.8%€221k▲ 559%€60k▼ 73.0%€49k▼ 18.8%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has fallen two years in a row; 2025 is 18% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.65M
Fixed assets
€1.54M▲ 12.9%
Current assets
€110k▲ 359%
Equity and liabilities €1.65M
Equity
€515k▲ 10.4%
Debt
€1.13M▲ 23.2%
The debt ratio rises from 66.4% to 68.8%: debt grows faster than equity.
Key figures and ratios
Solvency
31.2%▼
2024 · 33.6%
ROE
9.4%▼
2024 · 12.8%
ROA
2.9%▼
2024 · 4.3%
Debt
€1.13M▲
2024 · €920k
Debt ≤ 1 year
€722k▲
2024 · €630k
Debt > 1 year
€410k▲
2024 · €289k
Income taxes
€17k▼
2024 · €23k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.39M€1.65M▲
Fixed assets21/28€1.36M€1.54M▲
Tangible fixed assets22/27€411k€587k▲
Land and buildings22€397k€571k▲
Plant, machinery and equipment23€6k€10k▲
Furniture and vehicles24€8k€7k▼
Financial fixed assets28€951k€951k=
Current assets29/58€24k€110k▲
Amounts receivable within one year40/41€9k€81k▲
Trade receivables40€9k€78k▲
Other amounts receivable41-€3k
Cash at bank and in hand54/58€14k€28k▲
Deferred charges and accrued income490/1€570€1k▲
Equity and liabilities
Total equity and liabilities10/49€1.39M€1.65M▲
Equity10/15€466k€515k▲
Contributions10/11€19k€19k=
Reserves13€448k€496k▲
Distributable reserves133€448k€496k▲
Amounts payable17/49€920k€1.13M▲
Amounts payable after more than one year17€289k€410k▲
Financial debts170/4€289k€410k▲
Amounts payable within one year42/48€630k€722k▲
Current portion of amounts payable after more than one year42€20k€35k▲
Trade debts44€2k€72k▲
Suppliers440/4€2k€72k▲
Taxes, remuneration and social security45€12k€12k▼
Taxes450/3€10k€10k▼
Remuneration and social security454/9€2k€2k=
Other amounts payable47/48€596k€604k▲
Accrued charges and deferred income492/3€867€738▼
Income statement
Code20242025
Non-recurring operating income76A€0-
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€27k€54k▲
Other operating charges640/8€4k€7k▲
Non-recurring operating charges66A€511€0▼
Gross operating margin9900€123k€137k▲
Operating profit (loss)9901€92k€75k▼
Financial income75/76B€1€0▼
Recurring financial income75€1€0▼
Financial charges65/66B€9k€10k▲
Recurring financial charges65€9k€10k▲
Profit (loss) for the period before taxes9903€82k€66k▼
Income taxes67/77€23k€17k▼
Profit (loss) for the period9904€60k€49k▼
Profit (loss) for the period to be appropriated9905€60k€49k▼
Appropriation of the result
Profit (loss) to be appropriated9906€60k€49k▼
Transfer to equity691/2€60k€49k▼
To other reserves6921€60k€49k▼
The notes to these accounts (14 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
2025
31-12
Financial
Equity above €500kEq €515k ▲10.4%
8 profitable years in a row build equity to €515k.
24-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
19-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Highest result since 2018net €221k ▲559%
Operating result €305k, net result €221k, both a record.
31-12
Financial
Equity above €200kEq €406k ▲120%
6 profitable years in a row build equity to €406k.
12-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-12
Financial
Equity above €150kEq €152k ▲33.5%
4 profitable years in a row build equity to €152k.
08-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
31-12
Financial
Liquidity triplescurrent ratio 4.23
Current ratio from 1.49 to 4.23; short-term debt falls from €37k to €17k.
31-12
Financial
Equity above €100kEq €113k ▲36.5%
3 profitable years in a row build equity to €113k.
25-08
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 25 days late
2019
11-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
29-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 29 days late
2017
28-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 28 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Kortrijk · 1 establishment unit since 2015
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Overleiestraat(Kor) 528500 KortrijkGround area
392 m²
Building footprint
215 m²
Volume, LiDAR
1,295 m³
Parcel 34352F0621/00G000, Flanders · tallest building 13.5 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
JD Pharma
since 20152.246.252.358
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 34352F0621/00G000 | Flanders | 392 m² | 1 · 215 m² | 13.5 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Homie
BE 0631.983.704
Deerlijk · Eq €515k
SCHEPERS CONSULTING
BE 0807.234.097
Hasselt · Eq €515k
JST Consulting
BE 0643.954.492
Aalter · Eq €515k
2BINNOVATIVE
BE 0670.676.509
Herzele · Eq €514k
BLA
BE 0845.059.050
Antwerpen · Eq €514k
Of 24,641 companies in sector 64210 we hold annual accounts for 19,693. 13,569 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded05-10-2015
Fiscal year end31-12
Activities, NACEBEL
64200Holdings
64210Activities of holding companies
68201Renting and operating of own or leased residential real estate, excluding social housing
68203Renting and operating of own or leased non-residential real estate, excluding land
82990Other business support services
Sources
Crossroads Bank for EnterprisesNational Bank · 10 filingsAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.